Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia

American Journal of Health-System Pharmacy

Volumn 72, Issue 17, 2015, Pages S104-S109

  Bain, Jonathan ^a   Meyer, Andrew ^a  

^a MOSES H CONE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BIVALIRUDIN; BLOOD CLOTTING FACTOR 7A; CREATININE; LEPIRUDIN; ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; PIPECOLIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS HEMOFILTRATION; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACIST; PLATELET COUNT; RETROSPECTIVE STUDY; THROMBOSIS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTOPENIA;

AGED; ANTICOAGULANTS; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 84973431177     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/sp150018     Document Type: Article

References (13)

1. Warkentin TE, Sheppard JI, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000 Sep; 96(5):1703-8.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 Nov; 101(5):502-7.
3. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4:759-65.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):311S337S.
5. Linkins LA, Dans AL, Moores LK et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia. Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2) (Suppl):e495S-e530S.
6. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest. 2009 Jun; 135(6):1651-64.
7. Francis JL, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, in the treatment of hepatin-induced thrombocytopenia. J Thromb Haemost. 2003 July; Suppl 1.P1909.
8. Arepally G, Reynolds C, Tomaski A et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995; 104(6):648-54.
9. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr; 26(4):461-8.
10. Runyan CL, Cabral KP, Riker RR et al. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy. 2011 Sep; 31(9):850-6.
11. Skrupky LP, Smith JR, Deal EN et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010 Dec; 30(12):1229-38.
12. Eichler P, Friesen HJ, Lubenow N et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000; 96:2373-8.
13. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008 Sep; 28(9):1115-24.